US-based Lyric Pharmaceuticals has finished enrolling patients in a Phase II trial of LP101 (ulimorelin) for the treatment of enteral feeding intolerance (EFI) in critically ill patients.

The PROMOTE study enrolled 120 mechanically ventilated critically ill patients aged 18 years and above in whom EFI showed as a gastric residual volume measured at 500ml or more. The trial was conducted at sites in the US, Canada, Spain and the Netherlands.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

During the trial, patients were randomised to receive either LP101 (a macrocyclic agonist of the hormone ghrelin)  or metoclopramide.

“There is a serious unmet medical need for new drugs to treat this condition and ulimorelin holds considerable potential for these patients.”

Its primary efficacy objective is safety assessments and the evaluation of feeding success as measured by the proportion of patients’ daily protein prescriptions received through enteral nutrition.

PROMOTE lead investigator Daren Heyland said: “Enteral feeding intolerance is associated with significantly higher morbidity and mortality in patients with critical illness.

“Patients with EFI have lower nutritional intakes, fewer ventilator-free days, longer ICU stays, and higher 60-day mortality.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“There is a serious unmet medical need for new drugs to treat this condition and ulimorelin holds considerable potential for these patients.”

EFI is an acute disorder of gastric motor function that develops in critically ill, enterally tube fed patients. The disease prevents patients from receiving prescribed enteral feeding.

LP101 is currently under development for the treatment of EFI and other disorders affecting critically ill patients in the intensive care unit (ICU).